Diagnostic Definitions and Severity Stratification
The American Academy of Pediatrics (AAP, 2023) established evidence-based guidelines classifying childhood obesity as a chronic, complex neurobehavioral and metabolic disease, explicitly rejecting previous "watchful waiting" approaches.
Classification (CDC Growth Charts, Age 2–19 Years)
- Overweight: Body Mass Index (BMI) $85^{\text{th}}$ to $<95^{\text{th}}$ percentile for age and sex.
- Obesity (Class 1): $\text{BMI} \ge 95^{\text{th}}$ percentile for age and sex, or $\text{BMI} \ge 30\text{ kg/m}^2$ (whichever is lower).
- Severe Obesity (Class 2): $\text{BMI} \ge 120\%$ of the $95^{\text{th}}$ percentile, or absolute $\text{BMI} \ge 35\text{ kg/m}^2$.
- Severe Obesity (Class 3): $\text{BMI} \ge 140\%$ of the $95^{\text{th}}$ percentile, or absolute $\text{BMI} \ge 40\text{ kg/m}^2$.
Core Management Principles (AAP Guidelines)
flowchart TD
A["Screening: BMI ≥ 85th Percentile (Age ≥ 2 yr)"] --> B["Intensive Health Behavior & Lifestyle Treatment (IHBLT)<br/>(≥ 26 contact hours over 3–12 months, family-centered)"]
B --> C{"Age and BMI Severity Assessment"}
C -->|"Age ≥ 12 yr + BMI ≥ 95th Percentile"| D["Consider Pharmacotherapy as Adjunct to IHBLT<br/>(Semaglutide 2.4 mg weekly OR Liraglutide 3 mg daily)"]
C -->|"Age ≥ 6 yr + Confirmed Monogenic Obesity<br/>(POMC, PCSK1, LEPR, BBS)"| E["Setmelanotide (MC4R Agonist)"]
C -->|"Age ≥ 13 yr + Severe Obesity<br/>(BMI ≥ 35 with complications OR BMI ≥ 40)"| F["Evaluate for Metabolic & Bariatric Surgery (MBS)<br/>(Sleeve Gastrectomy / Roux-en-Y)"]
D --> G["Monitor Response at 12–16 Weeks<br/>(Target: ≥ 5% BMI reduction)"]
G -->|"Inadequate response / Poor tolerability"| H["Switch agent or evaluate for MBS"]
1. Intensive Health Behavior and Lifestyle Treatment (IHBLT)
- The baseline foundation for all pediatric weight management.
- Requires face-to-face, family-centered, multi-component interventions totaling $\ge 26\text{ contact hours}$ delivered over a 3 to 12-month period.
- Focuses on nutrient-dense dietary shifts, limiting sugar-sweetened beverages, reducing sedentary recreational screen time, promoting $\ge 60\text{ minutes/day}$ of moderate-to-vigorous physical activity, and adequate age-appropriate sleep.
Targeted Pharmacotherapy
Pharmacotherapy is indicated as an adjunct to IHBLT for adolescents aged $\ge 12\text{ years}$ with obesity ($\text{BMI} \ge 95^{\text{th}}$ percentile) or severe obesity.
| Drug Class & Name | Mechanism of Action | Approved Age & Indications | Titration Schedule & Dosing | Clinical Trial Evidence |
|---|---|---|---|---|
| Semaglutide (Wegovy) | Long-acting GLP-1 receptor agonist; enhances glucose-dependent insulin secretion, slows gastric emptying, and stimulates hypothalamic satiety centers | Age $\ge 12\text{ years}$ with $\text{BMI} \ge 95^{\text{th}}$ percentile | Subcutaneous (SC) injection once weekly. Start $0.25\text{ mg}$ weekly $\times 4\text{ wk}$; escalate monthly ($0.5 \rightarrow 1.0 \rightarrow 1.7\text{ mg}$) to target $2.4\text{ mg}$ weekly | STEP TEENS Trial (NEJM 2022): At week 68, mean reduction in BMI was $-16.1\%$ with semaglutide vs. $-0.6\%$ with placebo; $73\%$ of patients achieved $\ge 5\%$ weight loss |
| Liraglutide (Saxenda) | Daily GLP-1 receptor agonist; increases postprandial satiety and reduces appetite | Age $\ge 12\text{ years}$ with body weight $>60\text{ kg}$ and $\text{BMI} \ge 95^{\text{th}}$ percentile | SC injection once daily. Start $0.6\text{ mg}$ daily; increase weekly by $0.6\text{ mg}$ increments to maintenance $3.0\text{ mg}$ daily | Kelly et al. (NEJM 2020): Mean reduction in BMI SDS of $0.22$ vs. placebo at 56 weeks; $43.3\%$ achieved $\ge 5\%$ BMI reduction |
| Tirzepatide (Zepbound / Mounjaro) | Dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist | Age $\ge 10\text{ years}$ for T2D; adolescent severe obesity data | SC injection once weekly. Start $2.5\text{ mg}$ weekly $\times 4\text{ wk}$; escalate by $2.5\text{ mg}$ monthly to $5\text{ mg}$, $10\text{ mg}$, or max $15\text{ mg}$ weekly | SURPASS-PEDS & SURMOUNT-ADOLESCENTS: Dual incretin action achieves mean BMI reduction exceeding $18–20\%$, outperforming single GLP-1 agonists |
| Phentermine / Topiramate ER (Qsymia) | Phentermine: sympathomimetic amine releasing norepinephrine (anorectic). Topiramate: enhances GABA, inhibits AMPA receptors, suppressing appetite | Age $\ge 12\text{ years}$ with $\text{BMI} \ge 95^{\text{th}}$ percentile | Oral capsule once daily morning. Start $3.75/23\text{ mg} \times 14\text{ d}$, then $7.5/46\text{ mg}$. Max: $15/92\text{ mg}$ daily | EQUIP2 Trial: Mean BMI reduction of $-10.4\%$ at 56 weeks in adolescents compared to placebo |
| Setmelanotide (Imcivree) | Melanocortin-4 receptor (MC4R) agonist; restores impaired signaling in leptin-melanocortin pathway | Age $\ge 6\text{ years}$ with confirmed monogenic obesity: POMC, PCSK1, or LEPR deficiency, Bardet-Biedl syndrome (BBS) | SC injection once daily. Weight-based: $0.5–2\text{ mg}$ daily for $<6\text{ yr}$ or $<20\text{ kg}$; $1–3\text{ mg}$ daily for $\ge 20\text{ kg}$ | Clement et al. (Lancet Diabetes Endo): $>10\%$ weight loss at 1 year in $80\%$ of POMC and $45\%$ of LEPR deficiency patients; significant reduction in hunger scores |
Adolescent Metabolic and Bariatric Surgery (MBS)
Eligibility Criteria (AAP 2023 & ASMBS Guidelines)
- Age: Generally evaluated in youth aged $\ge 13\text{ years}$ who have reached Tanner Stage 4–5 pubertal maturation or final skeletal maturity.
- BMI Thresholds:
- Class 2 Severe Obesity ($\text{BMI} \ge 35\text{ kg/m}^2$ or $120\%$ of $95^{\text{th}}$ percentile) with major medical comorbidities: Type 2 diabetes mellitus, moderate-to-severe obstructive sleep apnea ($\text{AHI} > 5$), idiopathic intracranial hypertension (pseudotumor cerebri), or advanced MASH/NASH.
- Class 3 Severe Obesity ($\text{BMI} \ge 40\text{ kg/m}^2$ or $140\%$ of $95^{\text{th}}$ percentile) with or without comorbidities.
- Procedures:
- Vertical Sleeve Gastrectomy (VSG): Most common ($>80\%$ of pediatric cases); removes $\approx 80\%$ of the greater curvature, reducing ghrelin secretion.
- Roux-en-Y Gastric Bypass (RYGB): Creates small gastric pouch with Roux limb; reserved for severe GERD or poorly controlled T2D.
- Trial Evidence: Teen-LABS ($n=242$) and AMOS trials showed mean BMI reduction of $27\%$ at 3 years, complete remission of Type 2 diabetes in $95\%$, normalization of blood pressure in $74\%$, and resolution of dyslipidemia in $66\%$, with durable outcomes at 5–10 years.
Safety, Adverse Effects, and Monitoring
| Medication Class | Adverse Effects | Clinical Monitoring Protocol |
|---|---|---|
| GLP-1 Receptor Agonists (Semaglutide, Liraglutide) | Nausea, vomiting, diarrhea, constipation (transient during dose escalation). Cholelithiasis, pancreatitis, theoretical rodent risk of medullary thyroid carcinoma. | - Gradual 4-week titration intervals minimize GI distress. - Discontinue if severe epigastric pain radiating to back occurs (check amylase/lipase). - Contraindicated in personal/family history of Medullary Thyroid Carcinoma or MEN 2. |
| Dual GIP/GLP-1 Agonist (Tirzepatide) | GI intolerance, dyspepsia, hypoglycemia risk if co-administered with sulfonylureas or insulin. | - Monitor hydration and renal function (eGFR, BUN/Cr). - Avoid abrupt dose jumps. |
| Phentermine / Topiramate ER | Tachycardia, paresthesias, insomnia, cognitive slowing/memory lapses, metabolic acidosis, teratogenicity (orofacial clefts). | - Measure baseline and periodic serum electrolytes and bicarbonate. - Baseline heart rate and BP. - Mandatory REMS program: Monthly urine pregnancy test in post-menarcheal females before refills. |
| MC4R Agonist (Setmelanotide) | Skin hyperpigmentation (increased melanin synthesis), injection-site reactions, spontaneous penile erections, depression/suicidal ideation. | - Full-body dermatological examination for changing nevi. - Periodic psychological evaluation for mood disturbances. |
Long-Term Considerations
- Chronicity of Medical Therapy: Weight regain occurs rapidly following cessation of GLP-1 receptor agonists (up to two-thirds of lost weight regained within 1 year), underscoring that obesity pharmacotherapy functions as long-term disease maintenance rather than a short curative course.